Catalyst Wire Dossier Catalyst Wire Dossier

Rebif 44 µg

interferon beta-1a · Merck KGaA
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Rebif 44 µg, covering 2014-07-11 to 2014-07-11. Get the full timeline:

Most recent: Clinical Trial Update: An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

See pricing